Clinical Trials Logo

Renal Insufficiency, Chronic clinical trials

View clinical trials related to Renal Insufficiency, Chronic.

Filter by:

NCT ID: NCT02952092 Completed - Clinical trials for Hemodialysis Chronic Kidney Disease Patients With Anemia

A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia

Start date: November 30, 2016
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of ASP1517 compared to darbepoetin alfa in hemodialysis chronic kidney disease patients with anemia.

NCT ID: NCT02950142 Completed - Obesity Clinical Trials

Evidence-based Laboratory Test Order Sets in Primary Care

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

Cluster randomised controlled trial to evaluate what the effect is of evidence-based order sets aimed at five indications on the appropriateness of laboratory test ordering in primary care.

NCT ID: NCT02946034 Completed - Clinical trials for Chronic Kidney Disease

Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C

Start date: February 1, 2017
Phase: Phase 4
Study type: Interventional

Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.

NCT ID: NCT02945969 Completed - Clinical trials for Chronic Kidney Disease

Sodium Lowering and Urinary Protein Reduction Trial

SUPER
Start date: November 2016
Phase: Phase 3
Study type: Interventional

The proposed randomized controlled trial will test the effect of dietary sodium reduction on albuminuria in patients with proteinuric chronic kidney disease. Results from this study will clarify the role of dietary sodium reduction in management of patients with proteinuric chronic kidney disease and its potential to halt the progression of chronic kidney disease.

NCT ID: NCT02940860 Completed - Clinical trials for Chronic Kidney Disease

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Start date: November 29, 2016
Phase: Phase 3
Study type: Interventional

Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).

NCT ID: NCT02937350 Completed - Clinical trials for Chronic Kidney Disease

Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease

CLEAR
Start date: March 1, 2017
Phase: Phase 1
Study type: Interventional

The goal of this study is to better understand vitamin D catabolism and how it is affected by CKD and race.

NCT ID: NCT02933827 Completed - Clinical trials for Moderate to Severe Chronic Kidney Disease

Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease

Start date: May 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

1. To assess the safety of allogeneic injection of expanded ADSCs to patients with Moderate to Severe Chronic Kidney Disease 2. To assess the efficacy of allogeneic injection of expanded ADSCs to patients with Moderate to Severe Chronic Kidney Disease

NCT ID: NCT02925962 Completed - Hypertension Clinical Trials

Evaluation of an Electronic CKD Clinical Decision Support System (CDSS) in Clinical Care

CDSSR18
Start date: August 14, 2017
Phase: N/A
Study type: Interventional

The investigators propose a three-arm, pragmatic, cluster-randomized clinical trial based in primary care. Participating Primary Care Providers (PCPs) will be randomized to usual care or one of two intervention arms. The first intervention will evaluate the efficacy of an automated CDSS that utilizes the electronic health record (EHR) to facilitate triple marker test ordering, guideline implementation and BP management, compared with usual care, among patients with previous documentation of eGFRcreat <60 ml/min/1.73m2. The second intervention goes a step further, and will evaluate whether a CDSS plus a follow-up telephone call from a pharmacist (CDSS PLUS) can improve BP management and patient CKD and NSAID toxicity knowledge among the patients with CKD, compared with CDSS alone. The primary clinical outcome is BP level, with secondary outcomes related to processes of care and patient knowledge.

NCT ID: NCT02915601 Completed - Clinical trials for Chronic Kidney Disease

Bicarbonate Administration in CKD

Start date: January 15, 2017
Phase: N/A
Study type: Interventional

Low serum bicarbonate levels, even within the normal laboratory range, are strongly associated with increased risks of hypertension, endothelial dysfunction, cardiovascular disease and death. The current proposal will investigate whether bicarbonate administration in patients with chronic kidney disease (CKD) will improve the health and function of arteries and reduce the size of the left ventricle of the heart. Overall, the proposed research will provide important new scientific evidence upon which physicians can base recommendations to patients with CKD to decrease the risk of developing cardiovascular diseases.

NCT ID: NCT02915029 Completed - Clinical trials for Chronic Kidney Disease

Home-base Kidney Care in Zuni Indians

HBKC
Start date: October 2013
Phase: N/A
Study type: Interventional

People reach End Stage Renal Disease (ESRD) due to progressive chronic kidney disease (CKD). CKD is associated with increased risks for heart disease and death. The burden of chronic kidney disease is increased among minority populations compare to Caucasians. The Zuni Indians are experiencing an epidemic of chronic kidney disease is due primarily to the high rates of obesity and diabetes. The present study entitled Home-Based Kidney Care is designed to delay / reduce rate of ESRD by early interventions in CKD. Investigators propose to assess the safety and efficacy of conducting a full-scale study to determine if home based care delivered by a collaborative team composed of community health workers and University of New Mexico faculty will decrease the risk for the development and the progression of CKD.